Related Experiment Video
Updated: Sep 27, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
The Impact of Atrial Fibrillation on One-Year Mortality in Patients with Severe Lower Extremity Arterial Disease
Min-I Su1,2,3, Ying-Chih Cheng4,5, Yu-Chen Huang6,7,8
1Division of Cardiology, Department of Internal Medicine, Taitung MacKay Memorial Hospital, Taitung 950, Taiwan.
Insights
Atrial fibrillation (Afib) significantly increases mortality and major adverse cardiovascular events (MACEs) in patients with severe lower extremity arterial disease (LEAD). This finding highlights the importance of considering Afib in managing severe LEAD prognosis.
Area of Science:
- Cardiovascular Medicine
- Vascular Surgery
- Clinical Outcomes Research
Background:
- Atrial fibrillation (Afib) is known to be associated with lower extremity arterial disease (LEAD).
- The prognostic impact of Afib on severe LEAD outcomes remains incompletely understood.
- Severe LEAD poses significant risks for cardiovascular events and mortality.
Purpose of the Study:
- To investigate the association between atrial fibrillation (Afib) and clinical outcomes in patients with severe lower extremity arterial disease (LEAD).
- To determine if Afib independently predicts adverse events such as all-cause mortality and major adverse cardiovascular events (MACEs) in this patient population.
Main Methods:
- Retrospective enrollment of consecutive severe LEAD patients undergoing percutaneous transluminal angioplasty from January 2013 to December 2018.
- Patients were stratified based on the presence or absence of a history of Afib.
- Follow-up for at least one year, with primary outcome of all-cause mortality and secondary outcomes including cardiac-related mortality and MACEs.
Main Results:
- The study included 222 patients (74 ± 11 years, 54% male); 12.6% had acute limb ischemia.
- The Afib group exhibited significantly higher rates of all-cause mortality (42.9% vs. 20.1%, p=0.014) and MACEs (32.1% vs. 14.4%, p=0.028) compared to the non-Afib group.
- Afib was an independent predictor of all-cause mortality (adjusted HR: 2.153) and MACEs (adjusted HR: 2.338). Acute limb ischemia, Rutherford classification, and heart rate also independently predicted mortality.
Conclusions:
- Atrial fibrillation is significantly associated with increased risks of one-year all-cause mortality and MACEs in patients with severe LEAD.
- These findings underscore the critical prognostic role of Afib in severe arterial disease of the lower extremities.
- Further research is warranted to explore the potential benefits of oral anticoagulants in managing Afib patients with severe LEAD.
Abstract:
Atrial fibrillation (Afib) is associated with the presence of lower extremity arterial disease (LEAD), but its effect on a severe LEAD prognosis remains unclear. We investigated the association between Afib and clinical outcomes. We retrospectively enrolled consecutive severe LEAD patients undergoing percutaneous transluminal angioplasty between 1 January 2013 and 31 December 2018. Patients were divided according to the history of any type of Afib and followed for at least one year. The primary outcome was all-cause mortality. Secondary outcomes were cardiac-related mortality and major adverse cardiovascular events (MACEs). The study included 222 patients aged 74 ± 11 years (54% male), and 12.6% had acute limb ischemia. The Afib group had significantly higher rates of all-cause mortality (42.9% vs. 20.1%, p = 0.014) and MACEs (32.1% vs. 14.4%, p = 0.028) than the non-Afib group. Afib was independently associated with all-cause mortality (adjusted HR: 2.153, 95% CI: 1.084-4.276, p = 0.029) and MACEs (adjusted HR: 2.338, 95% CI: 1.054-2.188, p = 0.037). The other factors associated with all-cause mortality included acute limb ischemia (adjusted HR: 2.898, 95% CI: 1.504-5.586, p = 0.001), Rutherford classification, and heart rate. Afib was significantly associated with increased risks of one-year all-cause mortality and MACEs in patients with severe LEAD. Future studies should investigate whether oral anticoagulants benefit these patients.
More Related Videos
Related Concept Videos
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Aortic Regurgitation III: Medical Management
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease IV: Nursing Management
Hemodialysis I: Introduction

